Brief: Bylvay (Odevixibat) Approved In Japan For Rare Liver Disease Pfic
19/09/2025 13:00
Sept 19 (Reuters) - Ipsen SA IPN.PA: BYLVAY (ODEVIXIBAT) APPROVED IN JAPAN FOR RARE LIVER DISEASE PFIC Source text: ID:nGNEp6Sj0 Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ipsen SA
See all newsHealth Rounds: New blood test matches gold standard for liver disease diagnosis
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio